<< Back To Search

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Notify the Multiple Myeloma Research Foundation you are interested in this trial
NCT04566328
Age 18 +
Sex Both
Phase Phase 3
Third Opinion Trial Synopsis
Doctors are testing two different combinations of drugs to treat cancer in a trial. One combination has four drugs and the other has three. One of the drugs, bortezomib, can stop cancer cells from growing. Another drug, lenalidomide, can stop cancer cells from spreading. Daratumumab is a drug that can stop cancer cells from growing and spreading. Dexamethasone is a drug that lowers the body's immune response and is used with other drugs to treat cancer. The trial is trying to find out if adding bortezomib to the three-drug combination will work better at treating cancer, compared to just using the three-drug combination.
Third Opinion AI Generated Synopsis

Trial Summary
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
from ClinicalTrials.gov

Locations & Contact

Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: